New research published in Nature Medicine reveals that the medication dapagliflozin significantly reduces the risk of heart failure in patients who carry specific cardiomyopathy-associated genetic variants. Findings from the Mass General Brigham Heart and Vascular Institute and the Broad Institute of MIT and Harvard suggest that these genetic markers could help clinicians identify patients who derive a substantially larger benefit from the drug than the general population.
Why Genetic Screening Matters for Heart Failure Prevention
Historically, identifying a genetic variant linked to cardiomyopathy primarily served to inform patients of their elevated risk, often without a targeted preventative strategy. According to Dr. Shinwan Kany, a visiting scientist at the Cardiovascular Research Center, this new data demonstrates that specific tools, such as dapagliflozin, can effectively lower that risk.
The research, led by scientists at Mass General Brigham and the Broad Institute, highlights a shift toward genetically guided interventions. Dr. Christian T. Ruff, a cardiologist at Mass General Brigham and Senior Investigator at the TIMI Study Group, notes that this approach could protect vulnerable patients long before they begin to show outward symptoms of heart disease.
Dapagliflozin works by increasing the excretion of glucose and sodium in the urine. This process is thought to help the heart function more efficiently, which is why it is used to treat both type 2 diabetes and heart failure.
How Much Does Dapagliflozin Reduce Risk?
The study analyzed data from the DECLARE-TIMI 58 trial, a phase 3 clinical trial involving 12,685 participants with type 2 diabetes. Among this group, researchers identified 121 individuals carrying a cardiomyopathy variant. During a median follow-up of 4.2 years, the drug demonstrated a clear protective impact:
- Non-carriers: Dapagliflozin reduced heart failure hospitalizations by 32% compared to a placebo.
- Variant carriers: The drug reduced the risk of heart failure hospitalizations by approximately 80% compared to those who received a placebo.
Specifically, 16% of carriers in the placebo group were hospitalized for heart failure, compared to only 3% in the group treated with dapagliflozin. According to the study published in Nature Medicine, these protective effects were observed in participants regardless of their prior history of heart failure.
What Happens Next for Patients?
Dr. Nicholas A. Marston, a cardiologist with the Mass General Brigham Heart and Vascular Institute, emphasizes that cardiomyopathy variants represent an “actionable genotype.” This is particularly relevant for patients who have not yet developed established heart failure, a group for whom doctors might not otherwise initiate this specific treatment.
Because the trial focused exclusively on patients with type 2 diabetes, the researchers state that more study is required. Future investigations will need to determine if dapagliflozin offers the same level of protection for cardiomyopathy variant carriers who do not have diabetes.
Frequently Asked Questions
What is dapagliflozin?
Dapagliflozin is an SGLT2 inhibitor primarily used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease, according to the NHS and Drugs.com.
Can genetic testing change heart failure treatment?
Yes. According to researchers at Mass General Brigham, identifying cardiomyopathy-associated genetic variants can help clinicians pinpoint which patients are likely to see the greatest benefit from preventative treatments like dapagliflozin.
Does dapagliflozin treat type 1 diabetes?
No. The Mayo Clinic notes that dapagliflozin is not intended for patients with insulin-dependent or type 1 diabetes.
Always consult with your cardiologist or primary care provider regarding genetic screening. Understanding your unique genetic profile can help your medical team personalize your long-term heart health strategy.
Are you interested in learning more about how genetics are changing modern medicine? Subscribe to our newsletter for the latest updates on clinical research and heart health breakthroughs.